Associated Papers
Neuronopathic Gaucher disease: Beyond lysosomal dysfunction.
Arévalo NB et al.
Frontiers in Molecular Neuroscience, 2022
Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review.
Revel-Vilk S et al.
International Journal of Molecular Sciences, 2020
32998334 (PubMed )
Supplement: ijms-21-07159-s001.pdf
Exploring genetic modifiers of Gaucher disease: The next horizon.
Davidson BA et al.
Human Mutation, 2018
Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease.
Hamler R et al.
Analytical Chemistry, 2017
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
Stirnemann J et al.
International Journal of Molecular Sciences, 2017
Glucocerebrosidase Mutations in Parkinson Disease.
O'Regan G et al.
Journal of Parkinson's Disease, 2017
Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
Barkhuizen M et al.
Neurochemistry International, 2016
Development of targeted therapies for Parkinson's disease and related synucleinopathies.
Sybertz E et al.
Journal of Lipid Research, 2014
Select a paper to view details